Barriers to Breast Cancer Care for Women Presenting at District and Regional-Level Hospitals in Ghana: Findings From the African Breast Cancer-Disparities in Outcomes Ghana Study
Authors:
- Clement Tetteh NarhCNClement Tetteh Narh
- Maxwell AfetorMAMaxwell Afetor
- Lydia AziatoLALydia Aziato
- Isabel Dos-Santos-SilvaIDIsabel Dos-Santos-Silva
- Valerie McCormackVMValerie McCormack
- Verna VanderpuyeVVVerna Vanderpuye
- on behalf of the ABC-DO Ghana teamOTon behalf of the ABC-DO Ghana team
- David B. NarteyDNDavid B. Nartey
- Bismark S. DonkorBDBismark S. Donkor
- 1 October 2025
- journal article
- review article
- Published by American Society of Clinical Oncology (ASCO) in JCO Global Oncology
- Vol. 11 (11) , e2500275
Abstract
PURPOSE: The WHO Global Breast Cancer Initiative (GBCI) aims to improve breast cancer (BC) survival through early stage at diagnosis, prompt diagnostic evaluation, and appropriate multimodality treatment. Care pathway analysis helps to evaluate delay and dropouts through this process. Little is known about the BC care pathway of women first presenting at lower level of health systems in Africa. METHODS: Between March 2023 and February 2024, we prospectively recruited 243 women age ≥18 years in eight (six district, one regional and teaching) hospitals who, owing to breast symptoms, were referred for breast biopsy in the Oti and Volta regions of Ghana. We determined the percentages of biopsy uptake (study paid if needed), histology results receipt, survival, and treatment initiation and explored how patient-, family-, and health system–related factors influenced care pathways. RESULTS: Of the 243 women referred, 53 (21.1%) did not have biopsy taken for health system–related (n = 22, 41%) and participant-related (n = 26, 59%) reasons. Among 190 women who had a biopsy, 102 (54%) were malignant. The median time from first visit (recruitment) to obtaining biopsy results was 14 days (IQR, 9-27). Among malignant cases, 61% (62/102) were stage III/IV (GBCI pillar 1) and 65 (64%) of 102 initiated treatment (GBCI pillar 3) with a median time from first visit to treatment initiation of 76 days (IQR, 36-131). Thirty-seven (36%) women whose biopsies were malignant did not initiate treatment because of participant-related (19 [51%]) and health system–related (12 [32%]) factors. The 1-year survival was 76% (95% CI, 66 to 84). CONCLUSION: In a unique study of women from lower levels of the health system in Ghana, we observed large gaps in biopsy uptake and treatment access, but excellent pathology turnaround times.Keywords
This publication has 23 references indexed in Scilit:
- Breast Cancer Survival in Sub-Saharan Africa—Diversity Across DisparitiesJAMA Network Open, 2024
- The Global Breast Cancer Initiative: a strategic collaboration to strengthen health care for non-communicable diseasesThe Lancet Oncology, 2021
- Real-world challenges for patients with breast cancer in sub-Saharan Africa: a retrospective observational study of access to care in Ghana, Kenya and NigeriaBMJ Open, 2021
- Breast cancer survival and survival gap apportionment in sub-Saharan Africa (ABC-DO): a prospective cohort studyThe Lancet Global Health, 2020
- Breast cancer survival in sub‐Saharan Africa by age, stage at diagnosis and human development index: A population‐based registry studyInternational Journal of Cancer, 2019
- Delayed presentation and diagnosis of breast cancer in African women: a systematic reviewAnnals of Epidemiology, 2017
- Breast cancer in Africa: prevalence, treatment options, herbal medicines, and socioeconomic determinantsBreast Cancer Research and Treatment, 2017
- Typical and atypical presenting symptoms of breast cancer and their associations with diagnostic intervals: Evidence from a national audit of cancer diagnosisCancer Epidemiology, 2017
- Factors contributing to delays in diagnosis of breast cancers in Ghana, West AfricaBreast Cancer Research and Treatment, 2016
- Stage at diagnosis of breast cancer in sub-Saharan Africa: a systematic review and meta-analysisThe Lancet Global Health, 2016